Investors & Media

Press Releases

Date Title View
Toggle Summary SAGE Therapeutics Announces Closing of $138 Million Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass. , April 21, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 342,857 shares at
View HTML
Toggle Summary SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus
Phase 3 STATUS Trial - Randomized, Double-Blind, Placebo-Controlled Clinical Trial of SAGE-547 for the Treatment of Patients With SRSE - Expected to Initiate by Mid-2015
View HTML
Toggle Summary SAGE Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , April 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of
View HTML
Toggle Summary SAGE Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., April 13, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares in the offering are to be sold by SAGE.
View HTML
Toggle Summary SAGE Therapeutics Announces Presentations at Upcoming Scientific Conferences
Final SAGE-547 Super-Refractory Status Epilepticus Phase 1/2 Clinical Data to be Presented at Antiepileptic Drug and Device Trials Conference
View HTML
Toggle Summary SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in Mid-2015
Final SAGE-547 Phase 1/2 Clinical Data to be Presented at Annual Antiepileptic Drug and Device Trials Conference
View HTML
Toggle Summary SAGE Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
Multiple Clinical and Scientific Milestones Anticipated in 2015
View HTML
Toggle Summary SAGE Therapeutics Appoints New Vice Presidents to Lead Key Organizational Functions
Amy Schacterle, Ph.D. Joins SAGE as Vice President of Regulatory Affairs and Quality Assurance, Erin Lanciani as Vice President of Human Resources
View HTML
Toggle Summary SAGE Therapeutics Announces Participation in February Conferences
CAMBRIDGE, Mass. , Jan. 28, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced management will participate in three upcoming
View HTML
Toggle Summary SAGE Therapeutics Initiates Phase 2a Trial of SAGE-547 in Postpartum Depression
CAMBRIDGE, Mass. , Jan. 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced dose administration of the first patient in a Phase 2a
View HTML